An Introduction to Bladder Cancer
Bladder cancer is the most common malignancy involving the urinary system. While cisplatin-based chemotherapy and Bacillus Calmette-Guérin (BCG) remains the standard of care for muscle-invasive and non-muscle-invasive disease, respectively, the development of immune checkpoint inhibitors has transformed the management of advanced urothelial cancer, with atezolizumab, durvalumab and avelumab being approved for use following platinum-based chemotherapy or in as first-line treatment in platinum-ineligible patients. However, many patients fail to respond to these agents, and predictive biomarkers remain an unmet need. Emerging treatment options include combined immunotherapy approaches, targeted therapies and antibody-drug conjugates.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Bladder Cancer Content
Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder
touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]
Joaquim Bellmunt, ASCO 2021: 5-year Follow-up from the Phase 3 KEYNOTE-045 Trial
touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial […]
Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer
touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]
Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions
Oncology & Hematology Review. 2020;16(2):82-9 DOI: https://doi.org/10.17925/OHR.2021.16.2.82
Urothelial carcinoma is the most common histologic type of bladder cancer in the USA and Europe, accounting for 90% of all bladder cancers. It is the sixth most common type of cancer diagnosed in the USA, and the 10th leading cause of cancer death, with an estimated 17,980 deaths predicted in 2020.1 Although the 5-year survival […]
Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis
It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]
Petros Grivas, ESMO 2019 – Advances in metastatic urothelial cancer
We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer. Questions 1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04) 2. What progress has been made in identifying biomarkers of response […]
Arlene Siefker-Radtke, ESMO 2019 – KEYNOTE-866 Phase III trial in bladder cancer
We are joined by Arlene Sietker-Radtke (The University of Texas MD Anderson Cancer Center) at ESMO 2019 to discuss her presentation on the results from the KEYNOTE-866 trial (NCT03924856). This phase III study investigates perioperative pembrolizumab or placebo in combination with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer. Questions What are the limitations […]
Enrique Grande, ESMO 2019 – Advances in first-line treatment of urothelial cancer
Enrique Grande (MD Anderson Cancer Center) discusses evolving immunotherapy combination strategies in the first line treatment of urothelial cancer at ESMO 2019. Questions 1. In which patients with urothelial cancer is immunotherapy indicated as first-line therapy? (0:04) 2. How can we improve response rates to immune checkpoint inhibitors in patients with urothelial cancer? (0:09) 3. […]
Novel Options in Metastatic and Non-surgically Curable Bladder Cancer
European Oncology & Haematology. 2018;14(2):87–95 DOI: https://doi.org/10.17925/EOH.2018.14.2.87
Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 new cases and 165,000 deaths in 2012.1 More than 90% of bladder cancers are of urothelial cell origin and the remaining histological subtypes include either pure forms of histological variants, such as squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcoma, or […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!